Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medexus Pharmaceuticals Inc T.MDP

Alternate Symbol(s):  MEDXF

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its lead products are IXINITY (US), Rupall (Canada), Rasuvo (US) and Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.


TSX:MDP - Post by User

Comment by oceanelevenon May 20, 2021 3:02pm
187 Views
Post# 33241689

RE:RE:Revenue numbers

RE:RE:Revenue numbers7.10 shares will become free trading in June from the last tea & bake sale...we will have lots of juicy news to help us longs out...


The offering consisted of 4,581,689 units at a price of C$7.10 per unit for total gross proceeds of approximately C$32,529,992, including 597,611 units sold pursuant to the exercise in full of the over-allotment option.

The offering was led by Raymond James Ltd. and Stifel GMP, as co-lead underwriters and joint bookrunners, on behalf of a syndicate of underwriters consisting of Roth Canada, ULC, Bloom Burton Securities Inc. and Mackie Research Capital Corporation.

Each unit consists of one common share and one-half of one common share purchase warrant. Each warrant entitles the holder thereof to purchase one Common Share at a price equal to $10.00 until February 23, 2023.

In the event that the volume-weighted average trading price of the common Shares on the TSX Venture Exchange exceeds C$14.00 for ten consecutive trading days, the company may accelerate the expiry date of the warrants after notifying shareholders.

<< Previous
Bullboard Posts
Next >>